Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 369

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 369
---
 be no assurance
that any alternative courses of action to finance the Company would be successful.

This requirement for
additional financing in the short term represents a material uncertainty that may cast significant doubt upon the Group and Parent Company’s
ability to continue as a going concern. Should it become evident in the future that there are no realistic financing options available
to the Company which are actionable before its cash resources run out then the Company will no longer be a going concern. In such circumstances,
we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared
on a liquidation basis and assets would be stated at net realizable value and all liabilities would be accelerated to current liabilities.

Revenue

Revenue is accounted
for in line with principles of IFRS 15 ‘Revenue from contracts with customers.

Supply of Research and Development Services

Revenue from the supply
of services is subject to specific agreement. This is recognised over the contract term, proportionate to the progress in overall satisfaction
of the performance obligations (the services performed by the Group), measured by cost incurred to date out of total estimate of costs.
The primary input of substantially all work performed under these arrangements is labour. There is normally a direct relationship between
costs incurred and the proportion of the contract performed to date.

Where the Group supplies
services to a client it generally bills an agreed percentage in advance of the commencement of any work and the balance on completion.
Invoices to clients are payable under normal commercial terms.

Grant revenue

Where grant income is
received, which is not a direct re-imbursement of related costs, revenue is recognised at the point at which the conditions have been
met, this has been recognised within grant revenue. Where grants are received as a re-imbursement of directly related costs they are credited
to research and development expense in the same period as the expenditure towards which they are intended to contribute.

Business combinations and externally acquired intangible assets

Business combinations
are accounted for using the acquisition method at the acquisition date, which is the date at which the Group obtains control over the
entity. The cost of an acquisition is measured as the amount of the consideration transferred to the seller, measured at the acquisition
date fair value, and the amount of any non-controlling interest in the acquiree. The Group measures goodwill initially at cost at the
acquisition date, being:

| · | the fair value of the consideration transferred to the seller, plus; |

| · | the amount of